Superiority of selective bolus infusion and simultaneous rapid removal of anticancer agents by charcoal hemoperfusion in cancer treatment.
This report presents the clinical effectiveness of multidisciplinary therapy consisting of intraarterial selective chemotherapy, combined with radiofrequency regional hyperthermia (RFRH) in advanced cancer patients. Patients were categorized into the following therapeutic groups: Group I: RFRH without intraarterial chemotherapy. Group II: Intraarterial infusion of a standard dose of Mitomycin C (MMC) and 5Fu. Group III: RFRH combined with intraarterial chemotherapy as in Group II. Group IV: RFRH combined with a large intraarterial infusion of MMC or Adriamycin (ADM) during charcoal hemoperfusion. Clinical effectiveness in terms of more than 50% tumor size reduction was achieved in 9% in Group I, 0% in Group II, 25% in Group III and 55% in Group IV, respectively. In Group IV, several side effects were observed but were not serious, despite the lethal dose of drug administered. These results suggest that RFRH combined with selective infusion chemotherapy, especially when large doses are administered during charcoal hemoperfusion, is a valuable treatment for advanced cancer patients.
Kihara
T
T
Kidney Center, Tokyo Women's Medical College, Japan.
Nakazawa
H
H
Agishi
T
T
Honda
H
H
Ota
K
K
D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002606:Charcoal; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D005260:Female; D006464:Hemoperfusion / Q000379:methods*; D006801:Humans; D006979:Hyperthermia, Induced; D007261:Infusions, Intra-Arterial; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy* / Q000628:therapy
D002606:Charcoal